# GRI Bio (GRI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GRI
## Company Profile
- Ticker: GRI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 2 USD
- Market cap: 3559384.3799999994 USD
- Last updated: 2026-09-08
## Business Overview
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
## Why The Stock Is Moving

Following the latest company update, “GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars”, GRI closed down 30.6% at $2.00 on Sep 8, 2026. The move occurred in the trading session associated with this company update.

## Geographic Base

GRI is a U.S.-listed biotech entry with a small-cap development profile. It sits in biotechnology rather than medtech or services.

## Business Model

The business depended on early scientific progress, platform credibility, and access to capital. Investors historically watched whether the company could focus its pipeline and keep programs alive.

## Landscape Position

GRI occupies the historical small-cap biotech bucket. It is the type of name where the market cared most about whether the science could survive the financing cycle.

## Future Catalysts

- GRI Bio's catalyst setup now looks most tied to cough/shortness of breath, Commission, and the rest of its current pipeline. What gives this more shape is "The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621's differentiated therapeutic potential in idiopathic pulmonary fibrosis.... That setup makes the next update more important than the headline financials themselves. The partnership angle also matters here, especially around (6) the inability of the Company to identify, in-license or acquire additional technology.

## Drug Assets

- GRI-0621

## Recent News
- 2026-09-08 13:15 EST — [GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars](https://biopharmsignal.com/news/GRI/gri-bio-presents-new-phase-2a-data-at-ers-2026-defining-gri-0621-s-mechanism-of--98506305) — Source: GRI Bio
- 2026-08-27 14:01 EST — [GRI Bio Featured in "Why Now" On-Demand Video Webcast](https://biopharmsignal.com/news/GRI/gri-bio-featured-in-why-now-on-demand-video-webcast-98cf576b) — Source: GRI Bio
- 2026-08-24 14:05 EST — [GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026](https://biopharmsignal.com/news/GRI/gri-bio-to-present-late-breaking-phase-2a-gri-0621-data-highlighting-lung-functi-e0fd6400) — Source: GRI Bio
- 2026-06-18 13:31 EST — [GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis](https://biopharmsignal.com/news/GRI/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathi-36c7f058) — Source: GRI Bio
- 2026-05-14 13:35 EST — [GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline](https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differ-231c0da3) — Source: GRI Bio